Exicure Acquires GPCR Therapeutics to Enhance Cancer Treatment Innovations

Exicure Expands Its Therapeutic Portfolio with Strategic Acquisition of GPCR Therapeutics

Exicure, Inc. has recently solidified its commitment to advancing innovative cancer therapies through the acquisition of GPCR Therapeutics Inc., a strategic move that underscores Exicure's dedication to expanding its research and development capabilities in the biotechnology sector. On January 19, 2025, Exicure finalized a Share Purchase Agreement, acquiring all outstanding equity securities of GPCR Therapeutics USA Inc., a wholly owned subsidiary of GPCR. This acquisition takes place concurrently with the establishment of a License and Collaboration Agreement that focuses on leveraging GPCR's technologies, particularly in the realm of hematopoietic stem cell transplantation (HSCT).

The collaboration is structured to include milestone payments that hinge on the successful outcomes of clinical trials, marketing authorizations, and subsequent net sales, ensuring that both companies benefit from each stage of development. Furthermore, Exicure anticipates a recurring royalty payment of at least 10% of net sales, aligning their financial interests closely with the potential success of GPCR's innovative therapies. GPCR USA is currently conducting a Phase 2 clinical trial that aims to treat blood cancer patients eligible for HSCT. Led by Dr. Pina Cardarelli, the trial involves a combination treatment utilizing G-CSF, GPC-100 (Burixafor), and propranolol, with plans to enroll 20 patients by the end of April 2025 and share results by September.

Recent findings presented at the American Society of Hematology conference add to the excitement surrounding GPCR's clinical efforts. Interim results from the trial indicate that the new treatment regimen effectively mobilizes CD34+ stem cells for autologous transplantation, showcasing a notable improvement over existing therapies. One of the standout features of Burixafor is its ability to allow same-day administration of the mobilizing agent alongside leukapheresis, streamlining the process significantly compared to current FDA-approved treatments that necessitate overnight pre-treatment. With median engraftment times for neutrophils and platelets recorded at 11 and 14 days, respectively, the early outcomes appear promising, as all patients achieve the necessary priming for transplantation.

In addition to the acquisition, Exicure's strategic alignment with GPCR Therapeutics enhances its focus on addressing unmet medical needs within oncology. As the collaboration progresses, the companies aim to bring forward innovative therapies that could transform treatment protocols for blood cancer patients. This move not only strengthens Exicure's pipeline but also positions the company as a key player in the evolving landscape of cancer therapeutics.

Exicure’s acquisition of GPCR Therapeutics signals a notable shift in its operational strategy, emphasizing a commitment to cutting-edge therapeutic development. As both organizations work together to navigate the complexities of clinical trials and regulatory approvals, they set the stage for potentially transformative advancements in the treatment of blood cancers, benefiting patients and the broader healthcare community.